Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Solid Biosciences (SLDB) Shares Outstanding (Weighted Average) (2017 - 2024)

Solid Biosciences' Shares Outstanding (Weighted Average) history spans 8 years, with the latest figure at $41.4 million for Q3 2024.

  • For Q3 2024, Shares Outstanding (Weighted Average) rose 109.66% year-over-year to $41.4 million; the TTM value through Sep 2024 reached $41.4 million, up 109.66%, while the annual FY2023 figure was $19.9 million, 133.6% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q3 2024 was $41.4 million at Solid Biosciences, up from $39.5 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $100.9 million in Q2 2021 and bottomed at $3.5 million in Q4 2020.
  • The 5-year median for Shares Outstanding (Weighted Average) is $19.8 million (2023), against an average of $30.6 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) plummeted 92.55% in 2022 before it surged 162.81% in 2023.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $3.5 million in 2020, then surged by 105.58% to $7.1 million in 2021, then grew by 19.58% to $8.5 million in 2022, then surged by 133.6% to $19.9 million in 2023, then skyrocketed by 108.43% to $41.4 million in 2024.
  • Per Business Quant, the three most recent readings for SLDB's Shares Outstanding (Weighted Average) are $41.4 million (Q3 2024), $39.5 million (Q2 2024), and $38.2 million (Q1 2024).